- Active not recruitingPHASE1, PHASE2
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
This study is testing a new medicine, TAK-788 (also known as mobocertinib), for adults with a type of lung cancer. Researchers want to find the best dose, check for side effects, and see how it works in the body.
For: Carcinoma, Non-Small-Cell LungUnited States · China · Germany - Active not recruitingPHASE3
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
This study compares a new drug, TAK-788, with standard chemotherapy for advanced lung cancer (NSCLC) where the cancer has a specific genetic change (EGFR exon 20 insertion mutation). It's for people who haven't had prior treatment for their advanced cancer.
For: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)United States · Australia · Austria